Stock BAI BENEVOLENTAI
Add to a list
To use this feature you must be a member
Log inSign up

BenevolentAI Stock

Equities

BAI

LU2355630455

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam
Other stock markets
 11:12:03 2024-05-31 am EDT 		5-day change 1st Jan Change
0.56 EUR -.--% Intraday chart for BenevolentAI -2.78% -48.15%
May. 15 BenevolentAI Announces Further Success with AstraZeneca Collaboration as Novel Heart Failure Target Selected CI
May. 02 Benevolentai S.A. Announces Directorate Changes CI

Financials

Sales 2024 * 28.19M 35.91M 33.1M Sales 2025 * 22.66M 28.87M 26.6M Capitalization 58.2M 74.16M 68.34M
Net income 2024 * -26M -33.13M -30.53M Net income 2025 * -30M -38.22M -35.23M EV / Sales 2024 * 1.16 x
Net cash position 2024 * 25.58M 32.59M 30.03M Net cash position 2025 * 90.74M 116M 107M EV / Sales 2025 * -1.44 x
P/E ratio 2024 *
-2.88 x
P/E ratio 2025 *
-2.87 x
Employees 248
Yield 2024 *
-
Yield 2025 *
-
Free-Float 56.16%
More Fundamentals * Assessed data

Chart BenevolentAI

Dynamic Chart

Latest news about BenevolentAI

BenevolentAI Announces Further Success with AstraZeneca Collaboration as Novel Heart Failure Target Selected CI
Benevolentai S.A. Announces Directorate Changes CI
BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024 CI
BenevolentAI Founder Reportedly Calls for Board Revamp MT
BenevolentAI Founder Reportedly Calls for Board Revamp MT
Kenneth Mulvany Sends a Letter to Benovelent AI CI
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises AN
BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers CI
BenevolentAI Announces Executive Changes CI
BenevolentAI S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BenevolentAI Appoints Joerg Moeller as Executive Board Member CI
BenevolentAI Appoints Joerg Moeller as Chief Executive Officer CI
Oxford Nanopore appoints Keher to CFO as Cowper becomes COO AN
EARNINGS: Symphony bemoans "weak global demand"; Aseana sells assets AN
BenevolentAI S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news

Press releases BenevolentAI

BenevolentAI Announces Further Success With AstraZeneca Collaboration as Novel Heart Failure Target Selected BU
BenevolentAI - Result of Annual General Meeting AQ
BenevolentAI : Benevolent AI, - Result of Annual General Meeting PU
BenevolentAI: Result of Annual General Meeting BU
BenevolentAI : Major shareholding notifications Major shareholding notification PU
More press releases

News in other languages on BenevolentAI

Wall Street plane, le luxe atterrit en catastrophe
AVIS D'ANALYSTES DU JOUR : Kering, Axa, Eurofins, Hermès, Scor, Nexi, Fnac, Aperam, ArgenX...
Bolsa de Madrid: Wall Street está en vuelo y el lujo aterriza en catástrofe
MIDDAY BRIEFING - Unternehmen und Märkte
Merck KGaA : deux partenariats conclus dans l'IA
More news

Quotes and Performance

1 week-2.78%
1 month-12.50%
3 months-25.33%
6 months+7.69%
Current year-48.15%
More quotes

Highs and lows

1 week
0.56
Extreme 0.56
0.59
1 month
0.54
Extreme 0.54
0.64
Current year
0.54
Extreme 0.54
1.41
1 year
0.48
Extreme 0.48
2.66
3 years
0.48
Extreme 0.48
10.00
5 years
0.48
Extreme 0.48
10.00
10 years
0.48
Extreme 0.48
10.00
More quotes

Managers and Directors - BenevolentAI

Managers TitleAgeSince
Ivan Griffin FOU
 Founder 48 13-10-31
Catherine Isted DFI
 Director of Finance/CFO - 23-09-10
Constantinos Neophytou CTO
 Chief Tech/Sci/R&D Officer - 20-06-30
Members of the board TitleAgeSince
Nigel Shadbolt BRD
 Director/Board Member 68 20-06-30
Jean Raby BRD
 Director/Board Member 60 22-04-21
John Orloff BRD
 Director/Board Member 66 21-08-31
More insiders

Quotes

Date Price Change Volume
24-05-31 0.56 -.--% 5,830
24-05-30 0.56 -4.44% 6,638
24-05-29 0.586 -0.68% 5,122
24-05-28 0.59 +1.72% 3,600
24-05-27 0.58 +0.69% 5,180

Real-time Euronext Amsterdam, May 31, 2024 at 11:12 am EDT

More quotes

Company Profile

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery. The Company serves patients by leveraging its proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, and advancing in-house pipelines to inflection points.
Sector
Biotechnology & Medical Research
Calendar
2024-09-23 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for BenevolentAI

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.4773 GBP
Average target price
1.243 GBP
Spread / Average Target
+160.42%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BENEVOLENTAI Stock BenevolentAI
-48.15% 74.06M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.64B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BAI Stock